Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Branched-chain alpha-ketoacid dehydrogenase kinase (BCKDK)
- Target
- BCKDK
- Molecular classification
- Enzyme, Serine/threonine protein kinase, Mitochondrial protein
01
Overview
Branched-chain alpha-ketoacid dehydrogenase kinase (BCKDK) is a mitochondrial serine/threonine kinase that phosphorylates and inactivates the branched-chain alpha-ketoacid dehydrogenase (BCKDH) complex, which is the key regulatory point in the catabolism of the branched-chain amino acids leucine, isoleucine, and valine[1][3][7]. By phosphorylating BCKDH, BCKDK decreases BCAA degradation and affects metabolic pathways involving energy, protein synthesis, and lipid/glucose metabolism[1][4][2]. Deficiencies or dysregulations in BCKDK activity have been linked to inherited disorders (such as BCKDK deficiency and maple syrup urine disease), muscle-wasting diseases, aging, and emerging indications in cancer and metabolic syndrome[2][6]. BCKDK is a validated therapeutic enzyme target, with several classes of investigational small molecule inhibitors under research for metabolic and neoplastic disorders[3][6].
- Other names
- Branched chain keto acid dehydrogenase kinaseBCKDH kinaseBCKDHKINBDKBCKDKD[3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase (mitochondrial)branched chain alpha-ketoacid dehydrogenase kinaseBCKD-kinase
02
Mechanism of action
Inhibition of BCKDK increases BCKDH complex activity, promoting BCAA catabolism BCKDK inhibitors prevent phosphorylation of BCKDH, keeping it active
03
Biological functions
Regulation of branched-chain amino acid (BCAA: leucine, isoleucine, valine) catabolismPhosphorylation and inactivation of the BCKDH complexCoordination of BCAA metabolism with glucose and lipid metabolismMaintenance of muscle structure and function
04
Disease associations
Inherited metabolic disorders (e.g., Maple syrup urine disease, BCKDK deficiency)Muscle wasting disordersPossible roles in heart failure, metabolic diseases, and cancer
05
Safety considerations
Over-inhibition may lead to excessive BCAA catabolism and amino acid deficienciesPotential for impacting metabolic homeostasis including hypoglycemia and impaired muscle integrity
06
Interacting drugs
BT2 (experimental BCKDK inhibitor)
1 more in the full profile.
07
Biomarkers
BCKDK gene/protein expression levels (for muscle disease and possibly cancer/metabolic disease patient selection)Branched-chain amino acid and branched-chain ketoacid levels in blood
Beyond the preview
Go deeper on Branched-chain alpha-ketoacid dehydrogenase kinase (BCKDK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Branched-chain alpha-ketoacid dehydrogenase kinase (BCKDK).